Skip to content

    Onesource Specialty Pharma Limited

    ONESOURCEGood
    Healthcare·5 Aug 2025
    Management Summary

    OneSource Specialty Pharma delivered a strong Q1 FY26, characterized by significant margin expansion and a transition toward commercial-stage revenues. Management identified FY26 as a major inflection point, particularly as the company prepares for the global launch of Semaglutide generics starting in Q4. The strategic focus is currently on accelerating capacity and integrating two high-margin CDMO assets in Poland and Baroda.

    Highlights

    7

    • Revenue reported at ₹327.3 crores, representing a 12% YoY growth

    • EBITDA grew 37% YoY to ₹88.5 crores, with margins expanding 500 bps to 27%

    • Adjusted PAT turned positive at ₹37.1 crores compared to a loss in the previous year

    • Organic revenue guidance set at $400 million by FY28, with potential to exceed $500 million including M&A

    • Capacity expansion for drug-device combinations accelerated to 200 million units by end of CY2026

    • Successful completion of 25 inspections during the quarter, including USFDA and ANVISA approvals

    • Credit rating upgraded to the 'A' family, reflecting improved financial management

    Concerns

    1

    • Ongoing Judicial Matters with Novo Nordisk

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹327.3 Cr+12%YoY
    2. 02EBITDA₹88.5 Cr+37%YoY
    3. 03EBITDA Margin27%
    4. 04Adjusted PAT₹37.1 Cr
    5. 05Adjusted EPS₹3.2

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Organic Revenue Target
    $400 million
    		High
    Revenue
    Inorganic Revenue Contribution (Poland & Baroda)
    $100 million
    		High
    Capacity
    Cartridge and Vial Capacity
    200 million units
    		High
    Debt
    Debt-to-EBITDA Ratio
    below 1.5x
    		Medium
    Margin
    EBITDA Margin for Acquired Assets
    36% to 40%
    		High

    Risks & concerns

    5
    RiskSeverity

    Ongoing Judicial Matters with Novo Nordisk

    The matter involving partner Dr. Reddy's is sub judice; management refused to discuss details. — Management deflected

    high

    Temporary Leverage Increase

    Debt-to-EBITDA may temporarily exceed the 1.5x target due to accelerated capex investments. — Management acknowledged

    medium

    Seasonality in Base Business

    Antibiotics and cold products in the injectable/soft gelatine segments have inherent seasonal fluctuations. — Management acknowledged

    low

    Areas of Evasion(2)

    • Ongoing litigation with Novo Nordisk (sub judice)
    • Specific investment amount in Xbrane

    Q&A highlights

    3

    “Now when that approval comes and who comes first, I think it's really very difficult for anyone to answer that.”

    Investors are focused on the timing of the Semaglutide patent cliff; management admits approval timing is uncertain but remains confident in the complex product barrier.

    asked by Anand Mundra, Soar Wealth

    2 min read5 chapters

    Detailed Narrative

    01

    FY26 as a Strategic Inflection Point

    Management emphasized that FY26 represents a critical transition from pre-approval R&D revenues to commercial-scale supplies. While H1 is expected to be muted due to the execution of Master Service Agreements (MSAs), H2 is projected to see a significant pickup driven by commercial supplies of Semaglutide. The company has already secured confirmed purchase orders for these launches, providing high visibility into the second-half performance.

    02

    Inorganic Expansion and Global Footprint

    The Board has approved the evaluation of acquiring two CDMO assets in Poland and Baroda, which are currently promoter-held. These assets are expected to add at least $100 million in revenue and $36-$40 million in EBITDA by FY27. The Polish facility, which is USFDA approved for both pharma and biologics, provides OneSource with a crucial global footprint and de-risks customer concentration by offering an additional site for GLP-1 expansion.

    03

    GLP-1 Market Dynamics and Demand

    Despite news of innovators cutting guidance, OneSource reports that its generic customers are revising their forecasts upward. Management noted that current market numbers in regions like Canada and Brazil are constrained by supply rather than demand. With generic entry, they expect a significant volume surge driven by improved access and lower price points, particularly in underserved emerging markets.

    04

    Accelerated Capacity Expansion

    OneSource is accelerating its Phase 2 capacity expansion for drug-device combinations, aiming to have 200 million units of qualified capacity by the end of calendar year 2026. This is a significant advancement from the previous FY28 timeline. The expansion is supported by 'take-or-pay' contracts, which reinforce management's confidence in the high utilization of these new lines as markets open up.

    05

    Operational Excellence and Compliance

    The company maintained a perfect compliance record during the quarter, successfully navigating 25 inspections from regulatory agencies and customers. Key approvals were received from the USFDA and ANVISA, which management cited as a core competitive advantage in the complex injectable and biologics space. This track record is essential for securing long-term contracts with 'marquee' global pharmaceutical customers.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.